Replies to post #1331 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>What is the "current recombinant factor VIIa product" and who makes it?<

NovoSeven from NVO.

>How do we just step in and "enable the production and pricing of rhFVIIa at appropriate levels for broader utilization"? What does that mean?<

It means that a transgenically-produced FVIIa is likely to have a lower unit cost than NovoSeven, allowing LFB/GTC to capture market share and potentially expand the market for recombinant FVIIa to prophylactic use in addition to at-need use.

>I would appreciate an in depth discussion on rhFVIIa<

We discussed it a bit last week. Here are a few pointers:

#msg-13712057 (NovoSeven)
#msg-13735378 (how coagulation works)
#msg-13763492 (potential competition)
#msg-13784060 (abstract on surgical use)
#msg-13925693 (old NVO PR)

Also, you might want to check LFB’s English-language website:
http://www.lfb.fr/gb/index.asp